No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ENVB Enveric Biosciences
- 0.8806
- -0.0574-6.12%
Close Apr 19 16:00 ET
- 0.8960
- +0.0154+1.75%
Post 19:49 ET
6.42MMarket Cap-108P/E (TTM)
0.9500High0.8800Low131.66KVolume0.9200Open0.9380Pre Close118.63KTurnover1.84%Turnover RatioLossP/E (Static)7.29MShares6.980052wk High3.29P/B6.32MFloat Cap0.649052wk Low--Dividend TTM7.17MShs Float67500.0000Historical High--Div YieldTTM7.46%Amplitude0.6490Historical Low0.9010Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock
FibroGen, Acorda Therapeutics, Enveric Biosciences Among Healthcare Movers
SOL, MESO and ACOR Among Pre-market Losers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersARCA biopharma (NASDAQ:ABIO) stock moved upwards by 124.6% to $3.84 during Wednesday's pre-market session. The market value of their outstanding shares is at $55.6 million. Kintara Therapeutics
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionPartners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a P
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Nasdaq-listed psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) shared its financial results for the fourth quarter of 2023 and the fiscal year ended December 31, 2023, results showing:Cash in ha
Comments
2
Bioscience Company Signs Milestone Term Sheet For Joint Disease Treatment
Enveric Biosciences Embarks on a Milestone Journey with Exclusive Out-Licensing of New Chemical Entities for Joint Disease.
In an unprecedented move that signals a significant leap forward in the treatment of joint diseases, Enveric Biosciences has announced its decision to sign non-binding term sheets for the exclusive out-licensing of new chemical entities. These entities, specifically designed for both pharmaceutical and...
In an unprecedented move that signals a significant leap forward in the treatment of joint diseases, Enveric Biosciences has announced its decision to sign non-binding term sheets for the exclusive out-licensing of new chemical entities. These entities, specifically designed for both pharmaceutical and...
1
$Enveric Biosciences(ENVB.US$ Enveric Biosciences Canada Granted U.S. Patent #11931338: Nitrilated Psilocybin Derivatives and Methods of Using
$Enveric Biosciences(ENVB.US$
I should of known this stock was trash after seeing these two Crack heads
I should of known this stock was trash after seeing these two Crack heads
3
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg